文献速递关节外科

金属对金属髋关节翻修术的结局取决于失败原因:一项倾向性评分匹配研究

Outcomes After Metal-on-metal Hip Revision Surgery Depend on the Reason for Failure: A Propensity Score-matched Study.
PubMed 文献 · Clin Orthop Relat Res · 2018-01-01

该回顾性观察研究基于英格兰和威尔士国家关节登记系统(NJR),纳入2008年至2014年间因任何指征接受金属对金属髋关节(MoMHR)翻修的患者,按倾向性评分1:1匹配后比较因金属碎屑不良反应(ARMD)翻修与非ARMD翻修各1288例翻修(平均随访3年,范围1-7年)。结果显示ARMD翻修组再翻修风险低于非ARMD组(HR 0.52),死亡率在排除感染翻修后两组无差异;感染和脱位/半脱位翻修的5年假体生存率最低。

要点

  • ARMD翻修组与非ARMD翻修组术中并发症无差异(OR 0.97,95%CI 0.59-1.59,p=0.900)。
  • ARMD翻修组再翻修风险低于非ARMD组(HR 0.52,95%CI 0.36-0.75,p<0.001),排除感染翻修后仍较低(HR 0.59,95%CI 0.40-0.89,p=0.011)。
  • 感染翻修5年假体生存率81%(95%CI 55%-93%,p=0.003),脱位/半脱位翻修82%(95%CI 69%-90%,p<0.001),均低于ARMD翻修的94%(95%CI 92%-96%)。

核心结论

  • 与既往观察相反,因ARMD行MoMHR翻修者的再翻修风险约为非ARMD翻修者的一半。
  • 作者怀疑全球监管机构建议外科医生采用更低的翻修阈值,使ARMD翻修在更早期阶段进行,从而积极影响了再翻修率。
  • 感染和脱位翻修后的再翻修高风险令人担忧;感染性MoMHR翻修是非ARMD翻修后死亡率增加的原因,这与非MoMHR感染翻修的发现一致。

研究设计与样本

  • 回顾性观察研究,纳入英格兰和威尔士国家关节登记系统(NJR)中2008年至2014年间因任何指征接受MoMHR翻修的全部患者。
  • NJR患者同意率93%,关联手术能力95%;近期验证研究表明,NJR捕获的翻修手术数据完成度和准确性极佳。
  • 因ARMD和非ARMD指征翻修者按多个潜在混杂因素进行1:1倾向性评分匹配,匹配因素包括性别、年龄、初次关节置换类型、至翻修时间及翻修手术细节(入路、翻修的特定部件、股骨头大小、摩擦界面、植骨使用)。
  • 匹配队列共2576例MoMHR翻修,每组1288例翻修,两组平均随访均为3年(范围1-7年)。

主要发现

  • ARMD翻修组与非ARMD翻修组术中并发症无差异(OR 0.97,95%CI 0.59-1.59,p=0.900)。
  • ARMD翻修组死亡率低于非ARMD翻修组(HR 0.43,95%CI 0.21-0.87,p=0.019);从非ARMD指征组排除感染翻修后,两组死亡率无差异(HR 0.69,95%CI 0.35-1.37,p=0.287)。
  • ARMD翻修组再翻修率低于非ARMD翻修组(HR 0.52,95%CI 0.36-0.75,p<0.001);排除感染翻修后该差异持续存在(HR 0.59,95%CI 0.40-0.89,p=0.011)。
  • 与非ARMD组各具体翻修指征相比,感染翻修(5年假体生存率81%,95%CI 55%-93%,p=0.003)和脱位/半脱位翻修(5年假体生存率82%,95%CI 69%-90%,p<0.001)的假体生存率最低,ARMD翻修为94%(95%CI 92%-96%)。

临床怎么用

  • 作者怀疑全球监管机构建议外科医生采用更低的翻修阈值、使ARMD翻修在更早期阶段进行,从而积极影响了ARMD翻修后的再翻修率。
  • 作者认为感染和脱位翻修后的再翻修高风险令人担忧。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metal-on-metal hip replacement (MoMHR) revision surgery for adverse reactions to metal debris (ARMD) has been associated with an increased risk of early complications and reoperation and inferior patient-reported outcome scores compared with non-ARMD revisions. As a result, early revision specifically for ARMD with adoption of a lower surgical threshold has been widely recommended with the goal of improving the subsequent prognosis after ARMD revisions. However, no large cohorts have compared the risk of complications and reoperation after MoMHR revision surgery for ARMD (an unanticipated revision indication) with those after non-ARMD revisions (which represent conventional modes of arthroplasty revision). QUESTIONS/PURPOSES: (1) Does the risk of intraoperative complications differ between MoMHRs revised for ARMD compared with non-ARMD indications? (2) Do mortality rates differ after MoMHRs revised for ARMD compared with non-ARMD indications? (3) Do rerevision rates differ after MoMHRs revised for ARMD compared with non-ARMD indications? (4) How do implant survival rates differ after MoMHR revision when performed for specific non-ARMD indications compared with ARMD? METHODS: This retrospective observational study involved all patients undergoing MoMHR from the National Joint Registry (NJR) for England and Wales subsequently revised for any indication between 2008 and 2014. The NJR achieves high levels of patient consent (93%) and linked procedures (ability to link serial procedures performed on the same patient and hip; 95%). Furthermore, recent validation studies have demonstrated that when revision procedures have been captured within the NJR, the data completion and accuracy were excellent. Revisions for ARMD and non-ARMD indications were matched one to one for multiple potential confounding factors using propensity scores. The propensity score summarizes the many patient and surgical factors that were used in the matching process (including sex, age, type of primary arthroplasty, time to revision surgery, and details about the revision procedure performed such as the approach, specific components revised, femoral head size, bearing surface, and use of bone graft) using one single score for each revised hip. The patient and surgical factors within the ARMD and non-ARMD groups subsequently became much more balanced once the groups had been matched based on the propensity scores. The matched cohort included 2576 MoMHR revisions with each study group including 1288 revisions (mean followup of 3 years for both groups; range, 1-7 years). Intraoperative complications, mortality, and rerevision surgery were compared between matched groups using univariable regression analyses. Implant survival rates in the non-ARMD group were calculated for each specific revision indication with each individual non-ARMD indication subsequently compared with the implant survival rate in the ARMD group using Cox regression analyses. RESULTS: There was no difference between the ARMD and non-ARMD MoMHR revisions in terms of intraoperative complications (odds ratio, 0.97; 95% confidence interval [CI], 0.59-1.59; p = 0.900). Mortality rates were lower after ARMD revision compared with non-ARMD revision (hazard ratio [HR], 0.43; CI, 0.21-0.87; p = 0.019); however, there was no difference when revisions performed for infection were excluded from the non-ARMD indication group (HR, 0.69; CI, 0.35-1.37; p = 0.287). Rerevision rates were lower after ARMD revision compared with non-ARMD revision (HR, 0.52; CI, 0.36-0.75; p < 0.001); this difference persisted even after removing revisions performed for infection (HR, 0.59; CI, 0.40-0.89; p = 0.011). Revisions for infection (5-year survivorship = 81%; CI, 55%-93%; p = 0.003) and dislocation/subluxation (5-year survivorship = 82%; CI, 69%-90%; p < 0.001) had the lowest implant survival rates when compared with revisions for ARMD (5-year survivorship = 94%; CI, 92%-96%). CONCLUSIONS: Contrary to previous observations, MoMHRs revised for ARMD have approximately half the risk of rerevision compared with non-ARMD revisions. We suspect worldwide regulatory authorities have positively influenced rerevision rates after ARMD revision by recommending that surgeons exercise a lower revision threshold and that such revisions are now being performed at an earlier stage. The high risk of rerevision after MoMHR revision for infection and dislocation is concerning. Infected MoMHR revisions were responsible for the increased mortality risk observed after non-ARMD revision, which parallels findings in non-MoMHR revisions for infection. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Matharu GS, Judge A, Murray DW, et al. Outcomes After Metal-on-metal Hip Revision Surgery Depend on the Reason for Failure: A Propensity Score-matched Study. Clin Orthop Relat Res. 2018. PMID: 29529653. doi:10.1007/s11999.0000000000000029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。